Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
Status:
Withdrawn
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study test the hypothesis that the combination of simvastatin and
zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose
methylprednisolone and bendamustine on a day 1,8 schedule (to reduce toxicity) will be an
effective and well-tolerated treatment for relapsed and refractory multiple myeloma
Phase:
Phase 2
Details
Lead Sponsor:
James Graham Brown Cancer Center University of Louisville